📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
44 announcements match the current filters (relevance ≥ 5).
Senores Pharmaceuticals to Acquire Apnar Pharma for Rs 91 Crore Enterprise Value
Senores Pharmaceuticals has announced the 100% acquisition of Apnar Pharma Private Limited for an enterprise value of approximately Rs 91 crores. The deal includes taking over Rs 76 crores in debt and liabilities, with a cash equity contribution of Rs 15 crores funded via IPO proceeds and internal accruals. This acquisition provides Senores with a US-FDA, MHRA, and Health Canada approved manufacturing facility in Gujarat and 5 ANDAs with a total addressable market of $722 million. The transaction is expected to complete its first tranche by March 2026, facilitating backward integration and expansion into UK and Canadian markets.
Key Highlights
Total Enterprise Value of ~Rs 91 crores, including ~Rs 76 crores of debt and liabilities to be assumed by Senores.
Acquisition includes a US-FDA, MHRA, and Health Canada approved facility in Jambusar, Gujarat, with 50+ employees.
Wholly owned US subsidiary to acquire 5 ANDAs with a combined total addressable market of approximately $722 million.
Current annual capacity of 275 million tablets and 225 million capsules, with potential to expand up to 600 million and 500 million respectively.
Transaction to be executed in two tranches, with the first tranche closing in the current fiscal year by March 2026.
👀 What to Watch
Investors should monitor the successful integration of the Jambusar facility and the immediate commercialization of the 3 validated ANDAs. This move is likely to improve margins through backward integration and provide a platform for CDMO growth.
Senores Pharma to acquire Apnar Pharma for ~₹91 crore
Senores Pharmaceuticals Limited has announced the acquisition of 100% share capital of Apnar Pharma Private Limited in two tranches. The total enterprise value of the acquisition is approximately ₹91 crores. This includes taking over ₹76 crores of total debt plus expected liabilities related to the plant. The remaining ~₹15 crores will be paid in cash. The first tranche is expected to be completed by March 2026, and the second tranche by Q2 of FY 2027.
Key Highlights
Acquisition of 100% share capital of Apnar Pharma
Total Enterprise Value of ~₹91 crores
₹76 crores of debt and liabilities to be assumed
₹15 crores to be paid in cash
Apnar Pharma's turnover in March 2024 was INR 2756.26 Lakhs
👀 What to Watch
Investors should monitor the progress of the acquisition and its impact on Senores Pharmaceuticals' financials. Keep an eye on the integration of Apnar Pharma and potential synergies.
Senores Pharma launches Deferiprone Tablets in US market via Dr. Reddy's
Senores Pharmaceuticals, Inc. announced the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg, which will be marketed by Dr. Reddy’s Laboratories Inc. in the US market. This product is bioequivalent and therapeutically equivalent to Ferriprox Tablets of Chiesi USA, Inc. According to symphony data, Deferiprone Tablets, 500 mg & 1000 mg brand and generic products, had U.S. sales of approximately $70 million MAT for the twelve months ending in October 2025. Senores has a portfolio of 46 ANDAs and 133 strengths along with a pipeline of 22 ANDAs and 52 strengths.
Key Highlights
Deferiprone Tablets had U.S. sales of approximately $70 million MAT
Senores has a portfolio of 46 ANDAs and 133 strengths
Senores has a pipeline of 22 ANDAs and 52 strengths
8 ANDAs and 24 products permitted for distribution in the USA in CMO/CDMO vertical
Senores has over 394 product registrations and 824 product applications
👀 What to Watch
Investors should monitor the sales performance of Deferiprone Tablets in the US market and the impact on Senores Pharmaceuticals' revenue. Also, keep an eye on the progress of their ANDA pipeline.
Senores Pharma Receives Philippine FDA Approval for 10 Products
Senores Pharmaceuticals has received marketing authorizations from the Philippine FDA for 10 products across Cardiovascular, CNS, and Pain management therapies. The market size of these drugs in the Philippines is valued at US $23 million, representing a significant growth opportunity. This approval allows Senores to expand its footprint in Southeast Asia and provide affordable healthcare options. The company has 32 own ANDA and 32 CMO/CDMO commercial products permitted for distribution in the USA.
Key Highlights
Received Philippine FDA approval for 10 products
Market size of approved drugs in the Philippines is US $23 million
Company has 32 own ANDA products for distribution in the USA
Company has 32 CMO/CDMO commercial products for distribution in the USA
Company caters to more than 40 countries
👀 What to Watch
Investors should monitor Senores Pharmaceuticals' progress in the Philippines and its impact on revenue growth. Keep an eye on further regulatory approvals and expansion into other markets.
